Literature DB >> 11551644

Early detection of endogenous retroviruses in chemically induced mouse cells.

A S Khan1, J Muller, J F Sears.   

Abstract

Endogenous retroviral sequences are present as an integral part of eukaryotic genomes. Although the majority of these sequences are defective, a few can produce infectious virus, either spontaneously upon long-term culture or by treatment with various chemical or other agents. Early, extensive studies of retrovirus induction were done in mouse cells; however, similar studies have not been done using state-of-the-art virus detection assays and with cells of other mammalian species. To investigate induction and detection of occult retroviruses in cells of different species, especially primate cells that are used in production of biologics, we have initially determined the optimum conditions for retrovirus induction in chemically treated K-BALB mouse cells using highly sensitive product-enhanced reverse transcriptase (PERT) assays as well as transmission electron microscopy (TEM). Retrovirus induction was detected at day 1 post-drug treatment under all test conditions but was optimum using 30 microg ml(-1) of 5-iododeoxyuridine (IdU) for 24 h. Additionally, the combination of IdU and 5-azacytidine specifically enhanced activation of type C particles. RT activity was detected by PERT assays in one microliter equivalent of test sample and retroviral particle production was seen by TEM analysis. The induction of infectious murine leukemia retroviruses was confirmed by infectivity assays and correlated with PERT activity. These results indicate that strategies for detection of occult viral agents should include optimization of induction conditions using multiple viral detection assays to evaluate virus activation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11551644     DOI: 10.1016/s0168-1702(01)00280-5

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  7 in total

1.  Expression of human endogenous retrovirus type K (HML-2) is activated by the Tat protein of HIV-1.

Authors:  Marta J Gonzalez-Hernandez; Michael D Swanson; Rafael Contreras-Galindo; Sarah Cookinham; Steven R King; Richard J Noel; Mark H Kaplan; David M Markovitz
Journal:  J Virol       Date:  2012-05-16       Impact factor: 5.103

2.  Genetic Engineering of T Cells to Target HERV-K, an Ancient Retrovirus on Melanoma.

Authors:  Janani Krishnamurthy; Brian A Rabinovich; Tiejuan Mi; Kirsten C Switzer; Simon Olivares; Sourindra N Maiti; Joshua B Plummer; Harjeet Singh; Pappanaicken R Kumaresan; Helen M Huls; Feng Wang-Johanning; Laurence J N Cooper
Journal:  Clin Cancer Res       Date:  2015-03-31       Impact factor: 12.531

3.  Chemical induction of endogenous retrovirus particles from the vero cell line of African green monkeys.

Authors:  Hailun Ma; Yunkun Ma; Wenbin Ma; Dhanya K Williams; Teresa A Galvin; Arifa S Khan
Journal:  J Virol       Date:  2011-05-04       Impact factor: 5.103

4.  Regulation of the human endogenous retrovirus K (HML-2) transcriptome by the HIV-1 Tat protein.

Authors:  Marta J Gonzalez-Hernandez; James D Cavalcoli; Maureen A Sartor; Rafael Contreras-Galindo; Fan Meng; Manhong Dai; Derek Dube; Anjan K Saha; Scott D Gitlin; Gilbert S Omenn; Mark H Kaplan; David M Markovitz
Journal:  J Virol       Date:  2014-05-28       Impact factor: 5.103

5.  Validation of the safety of MDCK cells as a substrate for the production of a cell-derived influenza vaccine.

Authors:  David Onions; William Egan; Ruth Jarrett; Deborah Novicki; Jens-Peter Gregersen
Journal:  Biologicals       Date:  2010-09       Impact factor: 1.856

6.  LABRADOR-A Computational Workflow for Virus Detection in High-Throughput Sequencing Data.

Authors:  Izabela Fabiańska; Stefan Borutzki; Benjamin Richter; Hon Q Tran; Andreas Neubert; Dietmar Mayer
Journal:  Viruses       Date:  2021-12-18       Impact factor: 5.048

7.  Human endogenous retroviruses and cancer prevention: evidence and prospects.

Authors:  Luca Cegolon; Cristiano Salata; Elisabete Weiderpass; Paolo Vineis; Giorgio Palù; Giuseppe Mastrangelo
Journal:  BMC Cancer       Date:  2013-01-03       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.